Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 7, 2017, Audentes Therapeutics, Inc. (the Company) held
its 2017 Annual Meeting of Stockholders and the following
proposals were adopted:

1.

Election of three Class I directors, Jonathan
Silverstein, Thomas Schuetz and Thomas Woiwode, each to
serve three-year terms through the third annual meeting
of stockholders following the 2017 annual meeting and
until a successor has been elected and qualified or until
earlier resignation or removal:

Nominees

Shares For

Shares Withheld

Broker Non-Votes

Jonathan Silverstein

15,278,911

1,950,254

461,302

Thomas Schuetz

15,886,760

1,342,405

461,302

Thomas Woiwode

15,886,060

1,343,105

461,302

2.

Ratification of the appointment of KPMG LLP as the
Companys independent registered public accounting firm
for the fiscal year ending December 31, 2017:

Shares For

Shares Against

Shares Abstaining

Broker Non-Votes

17,688,871

1,396


About Audentes Therapeutics, Inc. (NASDAQ:BOLD)

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.